The Cooper Companies, Inc. (COO) Down 4.5% — Time to Rebalance My Portfolio?
The Cooper Companies, Inc. (COO) retreated sharply in the latest session, falling 4.55% to close at $76.55 — a loss of $3.65 from the prior day's close. After showing signs of stabilization in recent days, shares instead gave back meaningful ground, leaving sellers firmly in control and reinforcing a cautious near-term tone.
Trading activity compounded the bearish picture. Volume came in at roughly 5.30 million shares, well more than double the 90-day average of approximately 2.41 million. When a significant price decline is accompanied by unusually heavy turnover, it typically reflects genuine conviction behind the move — and here, that conviction was squarely to the downside. From the long-term perspective, the stock now sits about 16% below its 52-week high of $91.59, a stark reminder of how much ground has been lost since last year's peak and how persistent the headwinds have been.
Among large-cap healthcare stocks, COO's decline stood out as a notable underperformer compared to Abbott Laboratories (ABT), Intuitive Surgical (ISRG), and CVS Health (CVS). With shares sliding on elevated volume and still well off their highs, the near-term price action suggests the stock has yet to regain any meaningful momentum.
Why The Cooper Companies, Inc. Price is Moving Lower
The Cooper Companies, Inc. shares came under pressure following the company's Q1 2026 earnings report on March 5, which delivered a mixed message for investors. Revenue of $1.02 billion rose 6.2% year over year but fell short of estimates near $1.04 billion — a top-line miss that often weighs on health care equipment names when the market has priced in stronger execution. Non-GAAP EPS of $1.10 beat forecasts by roughly 6.8%, and GAAP EPS climbed 27% to $0.66, yet the market's reaction made clear that concerns over revenue quality and the nature of the earnings beat outweighed the bottom-line upside.
Management raised its full-year 2026 guidance, targeting revenue of $4.306 billion–$4.346 billion and non-GAAP EPS of $4.58–$4.66, underpinned by margin expansion, synergies, and stronger cash generation — with free cash flow now expected in the range of $600 million–$625 million. Even so, the stock's pullback reflects both valuation sensitivity and the caution warranted by regional variability flagged on the earnings call. With a profit margin of 9.16%, investors appear focused on whether incremental growth can translate into durably stronger profitability, rather than being driven primarily by cost savings and mix tailwinds. Analyst target adjustments and recent insider buying offered some support at the margins, but neither was sufficient to offset the pressure from the revenue miss and the heightened scrutiny.
What is the The Cooper Companies, Inc. Rating - Should I Sell?
Weiss Ratings assigns COO a C rating, with a current recommendation of Hold. That middling rating carries an important caveat: the risk/reward profile is less forgiving than many investors might expect from a Health Care name, largely because shareholder returns and trading behavior have both been unimpressive.
The most significant drag is performance and price behavior. COO carries a Weak Total Return Index and a Weak Volatility Index — a combination that signals shareholders have not been consistently rewarded for the risk they've taken on. Despite revenue growth of 4.59% and a 9.16% profit margin, the stock's recent risk-adjusted returns have lagged, which goes a long way toward explaining why the overall rating stays at Hold rather than moving higher.
Valuation adds another layer of concern. A forward P/E of 42.93 is a demanding multiple for a company posting modest top-line growth and a low 4.59% ROE. Put simply, expectations are elevated, and the margin for error is narrow — even a minor stumble in execution, pricing, or demand can weigh on returns even when operations are otherwise holding steady.
On the fundamental side, COO does have genuine strengths — including a Good Efficiency Index and an Excellent Solvency Index — but those positives have not translated into strong stock performance. Within the Health Care sector, Cooper Companies lands in the same Hold bucket as Abbott Laboratories (ABT, C), Intuitive Surgical, Inc. (ISRG, C), and CVS Health Corporation (CVS, C). It offers little rating-based rationale to favor it over the group while return and volatility metrics remain weak.
About The Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) is a Health Care company operating within the Health Care Equipment and Services industry, with a focus on specialized medical devices and related services. The business runs through two primary divisions: CooperVision and CooperSurgical. CooperVision is a global contact lens manufacturer offering a broad portfolio of soft contact lenses — including daily disposable, two-week, and monthly replacement options, as well as toric lenses for astigmatism and multifocal lenses for presbyopia. Its standing in the contact lens market is built on a diversified product lineup and long-established relationships with eye care professionals and distribution partners.
CooperSurgical serves hospitals, fertility clinics, and women's health providers with the devices and consumables used across fertility and assisted reproduction, in-office and surgical gynecology, and obstetrics. Its offerings span fertility solutions and cryostorage-related products, alongside surgical instruments and single-use supplies that demand consistent quality and reliable sourcing. Across both divisions, the company benefits from recurring demand tied to ongoing patient care and procedure volumes. At the same time, it navigates the practical challenges common to the Health Care Equipment and Services space: product lifecycle pressure, rigorous regulatory requirements, and dependence on clinical adoption and provider purchasing decisions.
Investor Outlook
With a Weiss Rating of C (Hold), The Cooper Companies, Inc. (COO) warrants a cautious approach as investors assess whether shares can hold recent support and reclaim key resistance levels without triggering renewed volatility. It's worth keeping a close eye on Health Care sentiment, reimbursement and regulatory developments, and any shifts in risk/reward signals that could weigh on the rating even as operating momentum remains relatively stable. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--